Clinical Trials List
2021-11-01 - 2024-07-31
Phase III
Recruiting5
ICD-10C82.50
Diffuse follicle center lymphoma, unspecified site
ICD-10C82.59
Diffuse follicle center lymphoma, extranodal and solid organ sites
ICD-10C83.10
Mantle cell lymphoma, unspecified site
ICD-10C83.19
Mantle cell lymphoma, extranodal and solid organ sites
ICD-10C83.30
Diffuse large B-cell lymphoma, unspecified site
ICD-10C83.39
Diffuse large B-cell lymphoma, extranodal and solid organ sites
ICD-10C83.80
Other non-follicular lymphoma, unspecified site
ICD-10C83.89
Other non-follicular lymphoma, extranodal and solid organ sites
ICD-10C84.90
Mature T/NK-cell lymphomas, unspecified, unspecified site
ICD-10C84.99
Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
ICD-10C84.A0
Cutaneous T-cell lymphoma, unspecified, unspecified site
ICD-10C84.A9
Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites
ICD-10C84.Z0
Other mature T/NK-cell lymphomas, unspecified site
ICD-10C84.Z9
Other mature T/NK-cell lymphomas, extranodal and solid organ sites
ICD-10C85.10
Unspecified B-cell lymphoma, unspecified site
ICD-10C85.19
Unspecified B-cell lymphoma, extranodal and solid organ sites
ICD-10C85.20
Mediastinal (thymic) large B-cell lymphoma, unspecified site
ICD-10C85.29
Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
ICD-10C85.80
Other specified types of non-Hodgkin lymphoma, unspecified site
ICD-10C85.89
Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
ICD-10C85.90
Non-Hodgkin lymphoma, unspecified, unspecified site
ICD-10C85.99
Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
ICD-10C86.4
Blastic NK-cell lymphoma
ICD-10C88.4
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9202.80
Other lymphomas, unspecified, extranodal solid organ sites
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Shih-Feng Cho Division of Hematology & Oncology
- 高育青 Division of Hematology & Oncology
- Jeng-Shiun Du Division of Hematology & Oncology
- Hui-Ching Wang Division of Hematology & Oncology
- Yi-Chang Liu Division of Hematology & Oncology
- Tsung-Jang Yeh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ya-Ping Chen Division of Hematology & Oncology
- Chun-Hui Lee 無
- Ya-Ting Hsu 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- - - 無
- HSIN-AN HOU 無
- WEI-LI MA 無
- CHENG-HONG TSAI 無
- Wen-Chien Chou 無
- KUAN-YIN KO 無
- Huai-Hsuan Huang 無
- 柯紀綸 無
- 田豐銘 無
- MING YAO 無
- BANG-BIN CHEN 無
- Chieh-Lung Cheng 無
- SHAN-CHI YU 無
- Chien-Chin Lin 無
- - - 無
- 劉高郎 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hao-Yuan Wang 無
- 陳玟均 無
- 李函叡 無
- Chia-Jen Liu 無
- 吳嘉紘 無
- 陳蓉宣 無
- Liang-Tsai Hsiao 無
- Po-Shen Ko Division of Hematology & Oncology
- Ting-An Lin 無
- Yao-Chung Liu 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
8 participants
-
Global
480 participants
